生物银行市场报告：2031 年趋势、预测与竞争分析

全球生物银行市场前景光明，为製药和生物技术公司、CRO、学术和研究机构以及医院市场提供了机会。预计到 2031 年，全球生物银行市场规模将达到 68 亿美元，2025 年至 2031 年的复合年增长率为 10.5%。该市场的主要驱动力是对基因检测和精准医疗日益增长的需求、新生儿脐带血干细胞储存的日益普及以及虚拟生物银行软体的出现。

• Lucintel 预测，基于产品或服务，设备将在预测期内实现最高成长。
• 根据应用，再生医学预计在预测期内仍将是最大的细分市场。
• 根据地区来看，预计亚太地区将在预测期内实现最高成长。

生物银行市场的策略成长机会

从各种可用应用程式来看，生物银行市场存在多种成长机会。透过利用这些机会，相关人员可以扩大参与度，并最终影响研究和公共卫生。本概述重点在于生物银行框架内的成长动态，解释关键的成长模式和不断扩大的市场地域范围所定义的广泛应用前景。

• 基因组学研究：基因库计划的趋势正在增加生物银行市场对此类设施的需求。生物库为基因组研究提供了多样化的群体和大量的样本。此应用将促进基因多态性、疾病发展和疾病管理治疗等领域的研究。生物库护理有望成为基因组学研究的一部分，有助于发展其他精准和靶向医疗领域。
• 个人化医疗：个人化医疗是生物库的机会温床，该领域的发展不容错过。生物库现在能够利用实际的生物检体和详细的临床病史来促进研究，以支持个人化治疗和药物发现。该应用将使患者的疾病诊断更加可靠、治疗更有针对性，进一步促进个人化医疗领域的发展。
• 公共卫生研究：生物库是流行病学研究以及基于健康的研究的重要样本来源，包括但不限于测量疾病发生、影响疾病发生的因素以及疾病控制和预防的研究。成长机会包括加强生物库资源，这对于流行病学和公共卫生方法至关重要。这将加强解决公共卫生问题以及製定和实施有效的卫生策略和计划的能力。
• 药物开发和临床试验：生物库是药物开发和临床研究的核心，因为它们提供满足所有需求的生物研究材料。参与这些机会意味着与製药和研究公司合作，满足他们的药物开发和临床研究需求。该应用加速了潜在药物的发现，同时改善了药物开发过程。
• 疾病特异性生物库：疾病特异性生物库的开发是另一个成长领域，有可能为癌症、心血管疾病、罕见遗传疾病等建立体质生物库。此类生物库对于提高我们对疾病、其生物标记和治疗方法的理解很有价值。该应用将促进特定的研究工作，同时也将进一步推动特定疾病的诊断和治疗需求。

战略生物银行错失了生物银行市场出现的机会。基因组学研究、个人化医疗、公共卫生研究、药物开发和特异性疾病的生物库代表着机会和影响不断增长的领域。利用这些机会将推动研究，改善个人医疗保健，并解决关键的公共卫生问题。

生物银行市场驱动因素与挑战

生物银行市场具有多种市场驱动因素和挑战，包括但不限于技术、监管和经济。相关人员需要了解市场驱动因素和挑战，以进入市场并利用不断增长的机会。

推动生物银行市场发展的因素有：

• 个人化医疗需求不断增加：近年来，由于对个人化医疗的日益重视，生物银行市场显着成长。 「个人化治疗」一词明确地建构了治疗的概念，这种治疗需要大量的生物和临床资料。生物库透过提供广泛、全面和复杂的样本收集来研究个人化医疗和改善医疗服务，从而满足这项要求。
• 纳入新的研究倡议领域：研究倡议范围的扩大，包括基因组学、流行病学和研究与开发，正在增加对生物库资源的需求。了解此类研究倡议的成长，我们需要更多特异性且易于取得的生物样本。为了做出有意义的科学贡献，生物库正在着手扩大其所持有的生物样本数量并扩大其范围以满足各种研究目的。
• 政府和机构的资金：政府和机构为生物银行建立和相关研究提供的资金通常是市场成长要素。资金将用于建立新的生物库、扩大现有的生物库以及改进和共用研究成果。在生物银行工作中增加投资有助于在不断研究的过程中产生先进的资源。
• 国际合作和资料共用：国际合作和资料共用正在刺激生物银行市场的成长，因此处理更大和异质的资料变得更加容易。透过国际伙伴关係和网络，研究和知识交流能力将得到释放。这些趋势透过利用人力和生物库资源来实现先前缓慢的研究，从而促进更好、更快的科学研究。

生物银行市场面临的挑战是：

• 监管和道德问题：对于生物银行，监管和道德合规不仅仅是市场力量。处理有关资料及其保护、相关人员同意和样本处理的政策是一项非常耗时且会产生大量成本的工作。人们认识到，为了维护生物库结构和营运框架的可信度和完整性，需要满足道德考量和监管方面。
• 资料安全、保护和隐私：资料安全和隐私相关问题是生物银行市场面临的挑战之一。保护高度个人化的健康和生物资料免遭洩露和未授权存取是一个问题。应采取网路安全实践和法律措施来保护生物质资料免受损害，并确保公众对生物库及其业务的信任。
• 成本和基础设施资源管理：建立和运作生物库需要大量的资金投入，这可能具有挑战性，尤其是对于较小的机构而言。所需的关键活动之一是在控制营运成本的同时获得设备、资讯技术系统和人力资源的资金。成本控制和良好的资源管理实践将是实现生物库永续性的关键因素。

人们进行了​​进一步的研究来解释得出这三个结论的具体原因，而生物银行的理论基础与许多应用科学社会学一样已经发展起来。此外，包括但不限于技术革命、医疗保健行业个人化趋势以及研究活动的成长等主要趋势正在塑造生物银行市场。解决这些驱动因素和市场问题对于利用成长机会、增强研究潜力和克服生物银行不断变化的现实至关重要。

目录

第一章执行摘要

第二章全球生物银行市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球生物银行市场趋势（2019-2024）及预测（2025-2031）
• 全球生物银行市场（按样本类型）
  • 血液製品
  • 人体组织
  • 细胞株
  • 核酸
  • 体液
  • 人类排泄物
• 全球生物银行市场（按产品和服务划分）
  • 装置
  • 耗材
  • 服务
  • 软体
• 全球生物银行市场应用情况
  • 再生医学
  • 生命科学研究
  • 临床研究
• 全球生物银行市场（按最终用途划分）
  • 製药和生物技术公司、CRO（委外研发机构）
  • 学术研究所
  • 医院

第四章区域市场趋势与预测分析（2019-2031）

• 全球生物银行市场（按地区）
• 北美生物银行市场
• 欧洲生物银行市场
• 亚太生物银行市场
• 世界其他地区的生物银行市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球生物银行市场成长机会（依样本类型）
  • 全球生物银行市场（按产品和服务）的成长机会
  • 全球生物银行市场的成长机会（按应用）
  • 全球生物银行市场成长机会（依最终用途划分）
  • 全球生物银行市场各区域成长机会
• 全球生物银行市场的新兴趋势
• 战略分析
  • 新产品开发
  • 全球生物银行市场产能扩张
  • 全球生物银行市场的企业合併
  • 认证和许可

第七章主要企业简介

• Thermo Fisher Scientific
• PHC Holdings
• Becton
• Dickinson and Company
• QIAGEN NV
• Merck KGaA
• Avantor
• Cryoport
• Tecan Trading
• Azenta

The future of the global biobanking market looks promising with opportunities in the pharmaceutical & biotechnology company and CRO, academic & research institute, and hospital markets. The global biobanking market is expected to reach an estimated $6.8 billion by 2031 with a CAGR of 10.5% from 2025 to 2031. The major drivers for this market are the growing demand for genetic testing and precision medicine, the rising popularity of preserving newborns' cord blood stem cells, and the emergence of virtual biobanking software.

• Lucintel forecasts that, within the product & service category, equipment is expected to witness the highest growth over the forecast period.
• Within the application category regenerative medicine will remain the largest segment in the forecast period.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Biobanking Market

The biobanking market is changing currently due to the occurrence of new technologies, the rise of new research, and changing policies. New trends signal the movement of biobanks in terms of operations, use of information, and the role played in biomedical research. Such trends are important to those interested in taking advantage of the new, fast-developing, biobanking environment.

• Advanced Technologies Adoption: In order to improve data analysis and sample processing, biobanks are integrating sophisticated tools such as high-throughput sequencing, NGS, and artificial intelligence among others. These technologies maximize the effectiveness of biobank tasks making it possible to conduct in-depth research to reveal genetic and environmental risk factors of health and diseases including illness and stress.
• Growth of Personalized Medicine: One of the trends of the market is also the old reason for the increasing loud demand for bank data that focuses on the cure of a certain disease. New populations and new clinical collections are also expanding and biobanks are making possible research into developing individualized therapies and precision medicine. This trend helps to develop more accurate treatment options and improve the efficacy of medical treatment.
• Safeguarding of Data and its Confidentiality: As focus increases with regard to data privacy and security, biobanks have implemented deep-rooted systems for the protection of such data. Adhering to regulatory frameworks like GDPR and HIPAA has become a vision, and biobanks have stepped up into new horizons of data security including the safeguarding of health and biological data and embracing confidentiality.
• Building of Centrally Managed and Region-Wise Located Biobanks: This current trend has been noticed in numerous countries where they are establishing a common biobank or biobanks with regional offices to enhance population-based studies and other health-related research on a large pop
• Combination of Biobanks and Sharing of Data: More emphasis is made on the increase of the combination, and sharing of data, of the biobanks and research institutions. There are emerging partnerships and networks that make it possible for scientists to utilize many datasets, from which a wide array of research can be pursued, speeding up the pace of discovery. This trend increases the worth of biobank resources and allows for more extensive and effective research.

Building of Centrally Managed and Region-Wise Located Biobanks: This current trend has been noticed in numerous countries where they are establishing a common biobank or biobanks with regional offices to enhance population-based studies and other health-related research on a large pop

Recent Developments in the Biobanking Market

Recent transitions in the biobanking market are characterized by improvements in technological infrastructural and research parameters. These developmental milestones are likely to revolutionize biobanking as they will offer new perspectives on biological sample collection, handling, and analysis for research. Knowledge of these developments is important for the players in the market to understand where the market is headed and identify new possibilities.

• Establishment of Large-Scale Biobanks: The establishment of large-scale biobanks like the All of Us Research Program in the U.S. and the European and Asian national biobanks is worth noting. These biobanks focus on harvesting a wide and rich array of biological samples to conduct extensive research population projects and customized treatment. They deepen the level of detail that can be addressed and assist cutting-edge research in genetics and population health.
• Combining the Various Areas of Genomics with High Throughput Technologies: The combining of genomics and biobanks with high-throughput practices is contributing to the development of research effort expansion. The standard operating procedures include high-throughput sequencing and genomic analysis which now allows the in-depth evaluation of genetic materials and how they affect health and disease. This advancement leads to the generation of more targeted and effective research, which in turn allows for deeper insights and the eradication of even more diseases.
• Biobank Information Management System's Improvements: The recent trends in biobank data management systems are enhancing the effectiveness and speed with which biobanks are operating. Improved techniques of handling the biorepository data as well as bioinformatics software help in proper structuring, dissecting, and disseminating the Biobank data. These systems facilitate the incorporation of different types of data sets and streamline the workflows, hence improving the research output.
• More Attention is Given to Bioethics and Regulations: More attention is paid to the ethical and regulatory perspectives of biobanking. There are measures being put in place by biobanks to make sure that ethics and governance principles such as consent, confidentiality, and sample handling are being followed. This concern improves the efficiency and reliability of the operations of biobanks and promotes compliance with accepted standards.
• Increasing the Scale of Biobank Networks and Advances in Collaborations: The growing network and collaboration of the biobanks is an interesting trend as the biobanks are ready to collaborate for sharing resources and data. These collaborations allow making use of the greater and more varied datasets, benefiting from the synergies of research, and speeding the process of science. Embedding biobanks into global networks helps achieve more complete and significant research results.

Important recent advances in the biobanking field such as the creation of population biobanks, adoption of new information technologies, progress in information management, fulfillment of regulative requirements, and enlargements of networks are defining the evolution of the markets. These changes broaden the possibilities of conducting biobanking research, facilitate personalized medicine, and bring about progress in the healthcare industry as well as in biomedical research.

Strategic Growth Opportunities for Biobanking Market

In the biobanking market, there are several opportunities for growth in terms of the different applications available. By applying these opportunities, stakeholders will be able to enlarge their engagement in and ultimately influence, research and public health. This overview focuses on the biobanking framework growth dynamics and explains the key growth patterns along with prospects for wider applications defined by the domain extension of the market.

• Genomics Research: The trends of Geno-bank initiatives are increasing the demand for such a facility in the biobanking market. The biobanks provide a variety of populations and a large sample for genomic research. This application promotes research in the fields of genetic polymorphism, disease development, and treatments in disease management. Transferring the care of biobanks is looking to portions of the genomics research that will help grow those in other areas of precise and targeted medicine.
• Personalized Medicine: Personalized medicine is a bane for biobank opportunities and the growth of this segment cannot be overlooked. Biobanks are now positioned to facilitate research with actual biological specimens and detailed clinical history in support of individualized therapies and drug discovery. This application allows a more reliable diagnosis and a treatment that better targets the disease of the patient and further promotes the development of the personalized medicine field.
• Public Health Research: Biobanks are sources of samples essential for health-based research as well as for epidemiological studies including but not limited to the studies measuring disease occurrence, factors influencing the occurrence of diseases, and their control or prevention. Growth opportunities include enhancing crucial biobank resources for epidemiological and public health approaches. This enhances the ability to solve public health problems as well as design and implement effective health strategies and programs.
• Drug Development and Clinical Trials: Biobanks are the heart of any drug development or any clinical studies, as they offer biological investigation material for all possible needs. Joining such opportunities means cooperation with pharmaceutical and research companies for the needs of drug development and clinical studies. This application hastens the generation of potential drugs while improving the processes of drug development.
• Disease-Specific Biobanks: Developing disease-specific biobanks is another area for growth as constitutive biobanks such as the ones for cancer, cardiovascular diseases, or rare genetic diseases may be set up. These biobanks are beneficial for the investigation of a better understanding of the disease, its biomarkers, and its treatment options. This application promotes specific research work, however, further advances the needs of diagnosis and treatment of specific diseases.

Strategic biobanking miscues opportunities emerging in the biobanking market. Genomics research, personalization medicine, public health research, drug development, and disease-specific biobanks indicate areas of growing opportunity and impact. Taking advantage of these opportunities engages progress in research, improves individual healthcare, and solves significant public health problems.

Biobanking Market Driver and Challenges

The biobanking market is characterized by various drivers and challenges, including, but not limited to, technology, regulation, and economy. Stakeholders need to appreciate such drivers and challenges in order to maneuver into the market and harness such opportunities that are ever on the rise.

The factors responsible for driving the biobanking market include:

• Increasing Demand Text for Personalized Medicine: Resent emphasis on personalized medicine is a major booster in the biobanking market. The term "personalized treatment" clearly structures the concept of therapy requiring a great amount of biological and clinical data needed to provide such treatment. Biobanks assist this requirement with their provision of broad, comprehensive, and elaborate sample collections to investigate personalized medicine and enhance healthcare services.
• Inclusion of New Areas in Research Initiatives: The demand for biobank resources is increasing because the scope of research initiatives including genomics, epidemiology, and drug development is broadening. Understanding the growth of these research efforts, there is therefore an increasing demand for more biological specimens that are specific as well as easily available and accessible. Biobanks have embarked on the process of increasing the number of biological specimens that they have and the scope at which they serve different research purposes to make meaningful scientific contributions.
• Government and Institutional Funding: Often, funding provided by the government and the institutions for building and biobanking and research related to it constitutes the core growing factor of the market. Funding helps to set up new biobanks and extend existing ones, to improve research work and to help share it. Increased investment in biobanking initiatives helps to create advanced resources during this period of constant research.
• International Collaboration and Data Sharing: International collaboration and data sharing are stimulating the growth of the biobanking market and due to this reason, it is easier to work with larger and more heterogeneous sets of data. Research and knowledge exchange capabilities are opened up through international partnerships and networks. This trend fosters better and faster science as research that would have taken longer to conduct is made possible by the availability of talent and biobank resources.

Challenges in the biobanking market are:

• Regulation and Ethical Issues: Regulatory and ethical compliance is more than one of the market forces for biobanking. Dealing with policies regarding the data and its protection, consent of parties and sample handling can be a very slow undertaking quite expensive. It is recognized that ethical considerations and regulatory aspects should be met to retain the credibility and integrity of the biobank structure and operational framework.
• Data Security, Protection, and Privacy: Data security and privacy-related issues are among the biobanking market challenges. Safeguarding very personal health-biological data from leakage and abusive access is an issue. Cybersecurity practices and legal measures should be performed to protect biomass data from harm and ensure public confidence in biobanks and their practices
• Costs and Infrastructure Resource management: Setting up and running biobanks will involve significant financial investments which particularly for small institutions can prove a challenge. One of the major activities that will be required is sourcing funds for equipment, information technology systems as well as human resources while controlling operational costs. Cost containment and proper resource management practices will be critical factors in the achievement of sustainability of the biobank.

Further studies have been done to illustrate specific reasons why these three conclusions should be achieved, the theoretical base of biobanking has been developed as much of the applied sociology of science. Further, the major forces including but not limited to the technological revolution, the personalization trend in the healthcare industry, and the growth in research activity take the shape of the biobanking market. Tackling these drivers and Market problems is essential for utilizing growth opportunities, increasing the research possibilities, and conquering the changing reality of biobanking.

List of Biobanking Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biobanking companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biobanking companies profiled in this report include-

• Thermo Fisher Scientific
• PHC Holdings
• Becton
• Dickinson and Company
• QIAGEN N.V.
• Merck KGaA
• Avantor
• Cryoport
• Tecan Trading
• Azenta

Biobanking by Segment

The study includes a forecast for the global biobanking market by sample type, product & service, application, end use, and region.

Biobanking Market by Sample Type [Analysis by Value from 2019 to 2031]:

• Blood Products
• Human Tissues
• Cell Lines
• Nucleic Acids
• Biological Fluids
• Human Waste Products

Biobanking Market by Product & Service [Analysis by Value from 2019 to 2031]:

• Equipment
• Consumables
• Services
• Software

Biobanking Market by Application [Analysis by Value from 2019 to 2031]:

• Regenerative Medicine
• Life Science Research
• Clinical Research

Biobanking Market by End Use [Analysis by Value from 2019 to 2031]:

• Pharmaceutical & Biotechnology Companies and CROs
• Academic & Research Institutes
• Hospitals

Biobanking Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Biobanking Market

The biobanking market has evolved positively due to technological advancements, increased research demands, and a focus on personalized medicine. Biobanks play a crucial role in medical research and therapy development by collecting and preserving biological specimens. Insights into the biobanking landscape in the USA, China, Germany, India, and Japan illustrate the scale and direction of the market amid changing policies and technologies.

• United States: In the U.S., biobanking has made significant strides through the integration of high-throughput gene sequencing and bioinformatics. Initiatives like the All of Us Research Program focus on broad data collection to improve services. Increased funding and public-private partnerships are enhancing biobank capabilities and supporting advances in disease therapeutics and research.
• China: China has heavily invested in its biobanking network, driven by government policies aimed at enhancing biotechnological capabilities and healthcare systems. This includes creating large-scale biobanks and forming collaborations with global organizations. China is also working to advance its legislative policies to ensure the ethical use and security of biological materials and data.
• Germany: Germany's biobank growth is supported by robust legislation and high standards for handling patient data and bioethics. The German Biobank Node promotes European data collection and sharing for scientific purposes. Recent efforts focus on integrating biobank data with clinical information to enhance research and precision medicine initiatives.
• India: India's biobanking segment is developing due to increasing research activities and government support for biomedical initiatives. New biobanks and expansions of existing ones, such as the Indian Genome Variation Consortium, are emerging. The country aims to strengthen infrastructure and data support for genomics, personalized medicine, and public health research through international partnerships.
• Japan: Japan's biobanking market is evolving through technological advancements and personalized medicine strategies. Recent developments include large-scale biobanks and partnerships with international counterparts. Japan is also working to integrate biobank data with electronic health records to improve research and clinical care while enhancing regulatory and ethical frameworks.

Features of the Global Biobanking Market

Market Size Estimates: Biobanking market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Biobanking market size by various segments, such as by product & service, sample type , application, end use industry, and region in terms of ($B).

Regional Analysis: Biobanking market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product & service, sample types , applications, end use industries, and regions for the biobanking market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biobanking market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the biobanking market by sample type (blood products, human tissues, cell lines, nucleic acids, biological fluids, and human waste products), product & service (equipment, consumables, services, and software), application (regenerative medicine, life science research, and clinical research), end use (pharmaceutical & biotechnology companies and CROs, academic & research institutes, and hospitals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Biobanking Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Biobanking Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Biobanking Market by Sample Type
  • 3.3.1: Blood Products
  • 3.3.2: Human Tissues
  • 3.3.3: Cell Lines
  • 3.3.4: Nucleic Acids
  • 3.3.5: Biological Fluids
  • 3.3.6: Human Waste Products
• 3.4: Global Biobanking Market by Product & Service
  • 3.4.1: Equipment
  • 3.4.2: Consumables
  • 3.4.3: Services
  • 3.4.4: Software
• 3.5: Global Biobanking Market by Application
  • 3.5.1: Regenerative Medicine
  • 3.5.2: Life Science Research
  • 3.5.3: Clinical Research
• 3.6: Global Biobanking Market by End Use
  • 3.6.1: Pharmaceutical & Biotechnology Companies and CROs
  • 3.6.2: Academic & Research Institutes
  • 3.6.3: Hospitals

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Biobanking Market by Region
• 4.2: North American Biobanking Market
  • 4.2.1: North American Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.2.2: North American Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.3: European Biobanking Market
  • 4.3.1: European Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.3.2: European Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.4: APAC Biobanking Market
  • 4.4.1: APAC Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.4.2: APAC Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals
• 4.5: ROW Biobanking Market
  • 4.5.1: ROW Biobanking Market by Product & Service: Equipment, Consumables, Services, and Software
  • 4.5.2: ROW Biobanking Market by End Use: Pharmaceutical & Biotechnology Companies and CROs, Academic & Research Institutes, and Hospitals

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Biobanking Market by Sample Type
  • 6.1.2: Growth Opportunities for the Global Biobanking Market by Product & Service
  • 6.1.3: Growth Opportunities for the Global Biobanking Market by Application
  • 6.1.4: Growth Opportunities for the Global Biobanking Market by End Use
  • 6.1.5: Growth Opportunities for the Global Biobanking Market by Region
• 6.2: Emerging Trends in the Global Biobanking Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Biobanking Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biobanking Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Thermo Fisher Scientific
• 7.2: PHC Holdings
• 7.3: Becton
• 7.4: Dickinson and Company
• 7.5: QIAGEN N.V.
• 7.6: Merck KGaA
• 7.7: Avantor
• 7.8: Cryoport
• 7.9: Tecan Trading
• 7.10: Azenta